Mometasone 0.1% cream
Requires a prescription from a doctor or prescriber
Mometasone is a corticosteroid not currently used in medical products.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Mometasone
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Mometasone
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
21 branded products available
MHRA licensed products
View all licensed products for Mometasone on the MHRA register
Elocon 0.1% cream
Elocon 0.1% cream
Elocon 0.1% cream
Ovixan 1mg/g cream
Mometasone 0.1% cream
Mometasone 0.1% cream
Mometasone 0.1% cream
Mometasone 0.1% cream
Mometasone 0.1% cream
Mometasone 0.1% cream
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(3)
Sinusitis (acute): antimicrobial prescribing (NG79)
PROPEL sinus implants for maintaining sinus patency after surgery (MIB253)
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (TA1134)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 10 · Randomised trials: 26 · 1996–2026
Showing the 50 most relevant studies, sorted by most relevant.
D. Passali, M. Spinosi, A. Crisanti, et al.
Multidisciplinary Respiratory Medicine, 2016
Robert C. Miller, David J. Schwartz, Jeff A. Sloan, et al.
International Journal of Radiation Oncology*Biology*Physics, 2010
- Mometasone Furoate
- Acute Disease
- Anti-Inflammatory Agents
Meghna Joseph, M. Krishna, Ancy Jenil-Franco, et al.
American journal of otolaryngology, 2024
- Adenoids
- Sulfides
- Acetates
Alisha Chohan, Avtar Lal, Karan Chohan, et al.
International Journal of Pediatric Otorhinolaryngology, 2015
- Mometasone Furoate
- Adenoids
- Anti-Inflammatory Agents
Almutairi RH, Albesher MB, Alboqami RA, et al.
2025
- Adenoids
- Sulfides
- Acetates
Mohya OH, Alghamdi AA, Alomar AA, et al.
2024
Alice Y. Ho, Molly Olm-Shipman, Zhigang Zhang, et al.
International Journal of Radiation Oncology*Biology*Physics, 2018
- Mometasone Furoate
- Acute Disease
- Breast Neoplasms
Christina Schnopp, Roland Remling, Matthias Möhrenschlager, et al.
Journal of the American Academy of Dermatology, 2002
- Mometasone Furoate
- Administration, Cutaneous
- Anti-Inflammatory Agents
Ru Chen, D. Zheng, Yajun Zhang, et al.
European Archives of Oto-Rhino-Laryngology, 2021
Pär Stjärne, Ralph Mösges, Mark Jorissen, et al.
Archives of Otolaryngology - Head and Neck Surgery, 2006
- Mometasone Furoate
- Administration, Intranasal
- Anti-Inflammatory Agents
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
5.8 hours
Mechanism
Unbound corticosteroids cross cell membranes and bind with high affinity to specific cytoplasmic receptors.
Food interactions
None known
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
5.8 hours
Protein binding
98%
Metabolism
Upon…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1161 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Upon in vitro incubation, one of the minor metabolites formed is 6ß-hydroxy-mometasone furoate. In human liver microsomes, the formation of the metabolite is regulated by cytochrome P-450 3A4.
Proteins and enzymes this drug interacts with in the body
PMID:27120390 PMID:37478846
Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors .
PMID:28139699
Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Involved in chromatin remodeling .
PMID:9590696
Plays a role in rapid mRNA degradation by binding to the 5' UTR of target mRNAs and interacting with PNRC2 in a ligand-dependent manner which recruits the RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leading to RNA decay .
PMID:25775514
Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth (By similarity)
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC R03AL12
ATC R01AD59
ATC R03AK14
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Mometasone
Additional database identifiers
Drugs Product Database (DPD)
7504
ChemSpider
390090
BindingDB
50237628
ZINC
ZINC000004097440
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7978
GenAtlas
NR3C1
GeneCards
NR3C1
GenBank Gene Database
X03225
GenBank Protein Database
31680
Guide to Pharmacology
625
UniProt Accession
GCR_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:8910
GenAtlas
PGR
GeneCards
PGR
GenBank Gene Database
X51730
GenBank Protein Database
35652
Guide to Pharmacology
627
UniProt Accession
PRGR_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2622
GenAtlas
CYP2C8
GeneCards
CYP2C8
GenBank Gene Database
M17397
Guide to Pharmacology
1325
UniProt Accession
CP2C8_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2638
GenAtlas
CYP3A5
GeneCards
CYP3A5
GenBank Gene Database
J04813
GenBank Protein Database
181346
Guide to Pharmacology
1338
UniProt Accession
CP3A5_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Linked open data from Wikidata (Q28208887), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.